menu
    • menu

    Company profile for ValenzaBio

    NEW Drugs in Dev: 2
    Evonik

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    ValenzaBio is a privately-held biopharmaceutical company developing therapies for autoimmune and inflammatory diseases. With a pipeline of differentiated monoclonal antibodies targeting clinically-validated mechanisms of action, we seek to provide improved therapies for patients with limited treatment options. Based in Bethesda, Maryland, in the heart of the capital biotech community, we strive to work collaboratively with all...
    ValenzaBio is a privately-held biopharmaceutical company developing therapies for autoimmune and inflammatory diseases. With a pipeline of differentiated monoclonal antibodies targeting clinically-validated mechanisms of action, we seek to provide improved therapies for patients with limited treatment options. Based in Bethesda, Maryland, in the heart of the capital biotech community, we strive to work collaboratively with all stakeholders while keeping our research and development efforts focused on the needs of patients.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ValenzaBioUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    6701 Democracy Blvd Suite 300 Bethesda, Maryland 20817
    Telephone
    Telephone
    212 945 8929
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.valenzabiotech.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    ACELYRIN Furthers Leadership Position Immunology with Acquisition of ValenzaBio
    ACELYRIN Furthers Leadership Position Immunology with Acquisition of ValenzaBio

    05 Jan 2023

    // BIOSPACE

    https://www.biospace.com/article/releases/acelyrin-inc-furthers-leadership-position-in-immunology-with-transformative-acquisition-of-valenzabio/?s=79

    BIOSPACE
    05 Jan 2023
    Share Share
    ProBioGen & ValenzaBio Enter Second Service Agreement
    ProBioGen & ValenzaBio Enter Second Service Agreement

    14 Jun 2022

    // CONTRACTPHARMA

    https://www.contractpharma.com/contents/view_breaking-news/2022-06-14/probiogen-valenzabio-enter-second-service-agreement/?widget=listSection

    CONTRACTPHARMA
    14 Jun 2022
    Share Share
    ValenzaBio Announces FDA Clearance of IND for VB421 in Thyroid Eye Disease
    ValenzaBio Announces FDA Clearance of IND for VB421 in Thyroid Eye Disease

    31 Mar 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220331006007/en

    BUSINESSWIRE
    31 Mar 2022
    Share Share
    ValenzaBio, Novelty Nobility Announce Exclusive License Agreement
    ValenzaBio, Novelty Nobility Announce Exclusive License Agreement

    15 Feb 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220215005384/en

    BUSINESSWIRE
    15 Feb 2022
    Share Share
    ValenzaBio, ProBioGen Enter Cell Line Pact
    ValenzaBio, ProBioGen Enter Cell Line Pact

    27 Jul 2021

    // CONTRACT PHARMA

    https://www.contractpharma.com/contents/view_breaking-news/2021-07-28/valenzabio-probiogen-enter-cell-line-pact/?widget=listSection

    CONTRACT PHARMA
    27 Jul 2021
    Share Share
    Lonza and ValenzaBio Enter Manufacturing Agreement to Rapidly Advance VB421
    Lonza and ValenzaBio Enter Manufacturing Agreement to Rapidly Advance VB421

    18 Jun 2021

    // PRESS RELEASE

    https://www.lonza.com/news/2021-06-18-15-00

    PRESS RELEASE
    18 Jun 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search